3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Vomiting
27
Nausea
17
Neoplasms
12
Breast Neoplasms
4
Multiple Myeloma
2
Lymphoma
2
Leukemia
2
Hematologic Neoplasms
2
Breast Neoplasms, Male
2
Weight Loss
1
Solid Tumors
1
Sarcoma
1
Rectal Neoplasms
1
Pain
1
Nausea With Vomiting Chemotherapy-Induced
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Inflammatory Breast Neoplasms
1
Hematologic Diseases
1
Glioma
1
Genital Neoplasms, Female
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Anorexia
1
Interventions
Gemcitabine
9
Paclitaxel
8
Carboplatin
7
atezolizumab
6
Sunitinib
5
navitoclax
4
Topotecan
4
Irinotecan
4
Docetaxel
4
Bevacizumab
4
pazopanib
3
liposomal doxorubicin
3
cobimetinib
3
Nivolumab
3
Erlotinib Hydrochloride
3
zolbetuximab
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
temsirolimus
2
selicrelumab
2
plocabulin
2
envafolimab
2
darinaparsin
2
brigimadlin
2
adavosertib
2
Tablets
2
Sorafenib
2
Rifampin
2
RG7388
2
Panitumumab
2
NVP-BKM120
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Solid Tumors
×
Palonosetron
×
Clear all
NCT02135510
2020-03-31
MEDEA
Amsterdam UMC, location VUmc
Phase 3
Completed
249 enrolled